A phase 2 study of ofatumumab (Arzerra®) in combination with a pan-AKT inhibitor (afuresertib) in previously treated patients with chronic lymphocytic leukemia (CLL)*

Christine I. Chen, Harminder Paul, Lisa W. Le, Ellen N. Wei, Susi Snitzler, Trina Wang, Olga Levina, Sumeet Kakar, Anthea Lau, Michelle Queau, James B. Johnston, Deborah A. Smith, Suzanne Trudel
  • Leukemia & Lymphoma, June 2018, Taylor & Francis
  • DOI: 10.1080/10428194.2018.1468892

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

http://dx.doi.org/10.1080/10428194.2018.1468892

The following have contributed to this page: Harminder Paul and Anthea Lau